These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16752937)

  • 21. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
    Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
    Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic treatment--side-effect and/or metabolic syndrome.
    Dadić-Hero E; Ružić K; Grahovac T; Palijan TZ; Petranović D; Sepić-Grahovac D
    Psychiatr Danub; 2011 Mar; 23(1):98-100. PubMed ID: 21448108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of atypical antipsychotics and weight gain.
    Sussman N
    J Clin Psychiatry; 2001; 62 Suppl 23():5-12. PubMed ID: 11603886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
    Deng C; Chen J; Hu C; Huang XF
    J Clin Psychopharmacol; 2010 Aug; 30(4):480-1. PubMed ID: 20631576
    [No Abstract]   [Full Text] [Related]  

  • 28. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 29. A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.
    Barnett M; Argo T; Alexander B; Perry P
    Ann Clin Psychiatry; 2006; 18(1):1-7. PubMed ID: 16517447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.
    Gentile S
    Drug Saf; 2006; 29(4):303-19. PubMed ID: 16569080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
    Koga M; Nakayama K
    Acta Psychiatr Scand; 2005 Jul; 112(1):75-6; discussion 77. PubMed ID: 15952949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-generation antipsychotics cause weight gain in youths.
    Harv Ment Health Lett; 2010 Jan; 26(7):7. PubMed ID: 20217902
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
    Schuster JP; Raucher-Chéné D; Lemogne C; Rouillon F; Gasquet I; Leguay D; Gierski F; Azorin JM; Limosin F
    J Clin Psychopharmacol; 2012 Oct; 32(5):672-7. PubMed ID: 22926602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schizophrenia, weight gain and atypical antipsychotics.
    Brown S
    Br J Psychiatry; 2006 Feb; 188():191-2. PubMed ID: 16449712
    [No Abstract]   [Full Text] [Related]  

  • 36. [Post-injection syndrome and olanzapine pamoate: A severe case report].
    Descusse A; Chebili S; Artiges E
    Encephale; 2017 Aug; 43(4):405. PubMed ID: 27349579
    [No Abstract]   [Full Text] [Related]  

  • 37. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
    Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D
    Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751
    [No Abstract]   [Full Text] [Related]  

  • 38. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
    Strassnig M; Miewald J; Keshavan M; Ganguli R
    Schizophr Res; 2007 Jul; 93(1-3):90-8. PubMed ID: 17478082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.